Evaluating the Diagnostic Precision of Transcranial Sonography-Magnetic Resonance Fusion Imaging in Distinguishing Parkinson’s Disease from Multiple System Atrophy—Parkinsonian Variant - Top-Institutions - MDSpire

Evaluating the Diagnostic Precision of Transcranial Sonography-Magnetic Resonance Fusion Imaging in Distinguishing Parkinson’s Disease from Multiple System Atrophy—Parkinsonian Variant

  • By

  • Chao Hou

  • Wei Zhang

  • Ji-zhu Xia

  • Hui Liu

  • Ming-xing Li

  • Wen He

  • Li-qing Peng

  • April 22, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Movement Disorders Center
    University of California, San Francisco (UCSF) Movement Disorders Center

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuroimaging

  • #2

    Mayo Clinic, Rochester
    Mayo Clinic, Rochester

    Rochester, MN

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neurodegenerative Diseases

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuroimaging

  • #4

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Germany

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuroimaging

  • #5

    National Institute of Neurological Disorders and Stroke (NINDS), NIH
    National Institute of Neurological Disorders and Stroke (NINDS), NIH

    Bethesda, MD

    Key Differentiators

    • Neurology
    • Neurodegenerative Disease Research
    • Neuroimaging

Original Source(s)

Evaluating the Diagnostic Precision of Transcranial Sonography-Magnetic Resonance Fusion Imaging in Distinguishing Parkinson’s Disease from Multiple System Atrophy—Parkinsonian Variant

  • by Chao Hou, Wei Zhang, Ji-zhu Xia, Hui Liu, Ming-xing Li, Wen He, Li-qing Peng

  • April 22, 2026

Related Content

This Week’s CGT News: Novo’s Parkinson’s Pivot

Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward

  • May 18, 2026

  • 7 min
Ferroptosis-immune crosstalk in CNS diseases: mechanisms and translational insights

Discrepancies in symptom concerns and burden from the perspectives of parkinson's disease patients, caregivers, and physicians